Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CYTK vs VNDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: CYTK 2 – 3 VNDA (1 Tie) Matrix Metrics: CYTK 5 – 5 VNDA

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CYTK carries a Unified Composite Score of 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin).

  • Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY).
  • Technical & Structure Timing Caution: CYTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CYTK vs VNDA
CYTK NASDAQ
Cytokinetics Inc.
Pharmaceutical Preparations
$53.18
-5.26% 1D
Market Cap $7.8B
TTM Revenue $113M
Forward P/E 117.7x
Beta / 30D Vol 1.09β · 58% Vol
Unified Composite Score
57.6 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.9%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $59.62 · SMA50: $63.72
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (CYTK 2 – 3 VNDA)

Columns: Metric · CYTK · VNDA
1. Valuation Multiples VNDA
Forward P/E 117.7x 103.1x
Trailing P/E 117.7x 103.1x
PEG Ratio N/M 2.23x
EV / Revenue 78.5x 0.9x
2. Growth & Scale CYTK
Revenue Growth (YoY) +2356.5% +24.1%
Earnings Growth (YoY) +0.0% -95.9%
TTM Revenue (USD) $113M $229M
Market Cap $7.8B $238.9M
3. Profitability & Quality VNDA
Gross Margin N/A 93.6%
Operating Margin -625.2% -77.6%
Net Profit Margin 0.0% -119.9%
Return on Equity (ROE) -572.1% -82.5%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$589M -$150M
Cash Flow Margin N/A -65.4%
Net Cash / Leverage $1.07B Net Debt $40M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CYTK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 68.8% (28th %ile) 163.3% (75th %ile)
Put/Call OI Skew 0.09x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CYTK (5) vs VNDA (5)
Institutional Metric CYTK VNDA Criterion Row Edge
Market Capitalization
Scale
$7.8B $238.9M Larger Scale CYTK
Trailing P/E Ratio
Valuation
117.7x 103.1x Lower Multiple VNDA
Forward P/E Ratio
Valuation
117.7x 103.1x Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+2356.5% +24.1% Higher Growth CYTK
Operating Margin (TTM)
Profitability
-625.2% -77.6% Higher Margin VNDA
Net Profit Margin
Profitability
0.0% -119.9% Higher Margin CYTK
Return on Equity (ROE)
Capital Efficiency
-572.1% -82.5% Higher ROE VNDA
52-Week Range Position
Momentum
1% ($53–$88) 4% ($4–$10) Stronger Trend VNDA
Beta / 30D Volatility
Risk Regime
1.09β · 58% Vol 1.25β · 61% Vol Lower Realized Risk CYTK
Unified Institutional Score
Composite Signal
57.6 / 100 (HOLD) 49.0 / 100 (HOLD) Higher Composite CYTK
Trailing 12M Revenue (USD)
Operating Scale
$113M $229M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 78.5x EV/Rev 2.23x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$589M ($1.07B Net Debt) -$150M ($40M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +8.33 pp
CYTK: -14.16% · VNDA: -5.83%
3M Horizon CYTK +0.12 pp
CYTK: -30.12% · VNDA: -30.24%
6M Horizon CYTK +8.32 pp
CYTK: -29.26% · VNDA: -37.58%
1Y Horizon VNDA +6.27 pp
CYTK: -18.83% · VNDA: -12.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CYTK Revenue VNDA Revenue CYTK Op. Margin VNDA Op. Margin Margin Leader
FY2018 $30M $190M -282.3% 11.3% VNDA
FY2019 $30M $230M -368.0% 10.0% VNDA
FY2020 $60M $250M -168.3% 11.0% VNDA
FY2021 $70M $270M -264.5% 15.7% VNDA
FY2022 $90M $250M -342.8% 2.5% VNDA
FY2023 $10M $190M -6589.7% -7.2% VNDA
FY2024 $20M $200M -2902.7% -20.5% VNDA
FY2025 $90M $220M -695.4% -70.0% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CYTK BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 68.8%
IV Percentile 28th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CYTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CYTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.8B market capitalization and -625.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CYTK vs VNDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CYTK carries a Unified Composite Score of 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin). Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY). Technical & Structure Timing Caution: CYTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CYTK leads the Growth & Scale pillar: CYTK posts +2356.5% YoY revenue growth and +0.0% YoY earnings growth on $113M TTM revenue (N/A gross margin, -625.2% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CYTK cumulative revenue shifted +200.0% while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, CYTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.

VNDA screens cheaper on headline valuation multiples. CYTK trades at 117.7x Forward P/E, 117.7x Trailing P/E, N/M PEG, and 78.5x EV/Revenue (unreported FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CYTK (-572.1% ROE) versus VNDA (-82.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CYTK carries 68.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.09β · 58% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.